ForumIAS LATEST
- SFG 2027 Level-1 starts 21 Dec. 2026 at 7 AM | Entrance Test on 22 Nov. at 9:30 AM Click Here to know more →
- Interview Guidance initiative by ForumIAS – UPSC CSE 2026 Click Here to know more →
- FRC 2027: SFG Residential program | accepting application for Tranche-2 Click Here to know more →
News: A study found that CancerSpot, a blood-based cancer detection test, detected 72% of cancer cases, with a false-positive rate of 1.4%.
About CancerSpot Test

- It is a blood test that uses DNA sequencing and Artificial Intelligence (AI) to detect cancer-related changes in DNA.
- Developed By: It is developed by Bengaluru-based Strand Life Sciences.
- Working Mechanism:
- DNA Release: Cells in the body release small DNA fragments into the bloodstream, known as circulating or cell-free DNA.
- In cancer patients, some fragments originate from tumour cells.
- DNA Analysis: The test combines DNA sequencing with AI to examine patterns of DNA methylation, which refers to chemical modifications of DNA that influence gene function.
- Cancer Detection: These methylation patterns differ between cancer cells and normal cells.
- The test analyses these differences to identify cancer-related signals in blood samples.
- DNA Release: Cells in the body release small DNA fragments into the bloodstream, known as circulating or cell-free DNA.
- Key Features:
- Multiple Cancer Detection: It aims to detect multiple types of cancer through a single blood test without requiring a tissue biopsy for initial detection.
- Clinical Evaluation: It was evaluated across 14 cancer types, involving 1,480 participants and 43 hospitals across India.
- Detection Accuracy: In an independent validation cohort, it detected 72% of cancer cases, with a false-positive rate of 1.4%.
- Limitation: Independent validation is needed before translating the findings into cancer screening strategies.



